PT Bundamedik Tbk

PT Bundamedik Tbk

IIDX:BMHS
199.00
IDR
+3.00
(+1.53%)
0.23EPS
1.52TMarket Cap
Nov 03Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
99.06
112.15
133.45
385.65
192.79
172.98
208.37
216.37
188.77
Basic EPS, GAAP
0.6
2.31
10.32
43.75
9.67
0.87
1.6
1.66
-0.13
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1.9
1.7
1.23
8.33
16.31
2.65
8.57
2.2
0.57
Book Value per Share
57.51
71.9
118.18
180.25
185.53
184.79
199.16
226.64
225.75
Tangible Book Value per Share
57.51
71.9
118.18
174.34
174.51
173.77
188.14
215.63
214.74
Basic Weighted Avg Shares
8,603
8,603
8,603
4,903
8,603
8,603
7,461
7,461
8,603
Sales/Revenue/Turnover
852,233
964,893
1,148,144
1,890,800
1,658,688
1,488,197
1,554,685
1,614,341
1,624,086
Operating Margin (%)
9.12
10.08
14.75
25.18
13.05
5.89
5.66
5.8
5.85
Depreciation Expense
38,663
45,001
58,290
71,410
108,537
113,554
113,699
122,705
115,778
Net Income, GAAP
5,128
19,895
88,791
214,489
83,228
7,461
11,944
12,419
-1,088
Effective Tax Rate (%)
50.07
31.08
18.3
22.42
27.07
59.75
51.04
34.47
84.76
Profit Margin (%)
0.6
2.06
7.73
11.34
5.02
0.5
0.77
0.77
-0.07
Working Capital
19,779
-27,485
206,901
394,609
243,968
299,415
520,465
464,154
513,330
LT Debt
482,690
443,214
387,917
229,437
457,963
688,431
699,941
840,226
987,818
Total Equity
532,228
665,594
1,100,344
1,796,216
1,808,232
1,800,036
2,147,736
2,394,507
2,381,746
Return on Invested Capital (%)
- -
5.88
8.69
16.36
5.92
1.27
1.38
1.66
0.26
Return on Capital (%)
- -
4.19
6.12
3.96
2.5
0.66
1.11
0.99
0.15
Return on Common Equity (%)
- -
3.57
10.86
16.71
5.29
0.47
0.72
0.68
-0.06

Capital Structure

IDR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
515,561
516,545
509,827
LT Borrowings
721,891
784,809
891,819
LT Finance Leases
118,335
105,216
96,000
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8,603
8,603
8,603
Market Capitalization
1,634,649
1,634,649
1,522,805

Working Capital

IDR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,210,239
1,224,556
1,233,039
Cash, Cash Equivalents & STI
246,095
283,937
237,219
Accounts Receivable, Net
161,940
167,794
181,990
Inventories
51,620
56,312
48,393
Total Current Liabilities
746,085
721,025
719,709
Payables & Accruals
- -
- -
- -
ST Debt
515,561
516,545
509,827
Deferred Revenue
- -
- -
- -

Growth Rates

IDR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
18.85%
11.49%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
10.68%
3.98%
Sales/Revenue/Turnover
- -
10.09%
3.84%
Total Cash Common Dividend
- -
110.68%
-74.34%

Quarterly Revenue

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
413,751
370,730
372,470
397,734
1,554,685
2025
379,030
378,770
397,092
459,448
1,614,341
2026
371,094
396,451
- -
- -
- -

Quarterly Earnings Per Share

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.26
0.01
0.1
0.02
1.6
2025
0.38
0.07
0.97
0.02
1.66
2026
0.01
-1.12
- -
- -
- -

Quarterly Dividends Per Share

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.31
5.76
8.57
2025
- -
- -
- -
0.57
2.2
2026
- -
- -
- -
- -
- -

Company Description

CEO
Agus Heru Darjono
Full Time Employees
1,566
Sector
Health services
Industry
Hospital/Nursing management
Address
Jl. Teuku Cik Ditiro No.28 Jakarta Pusat JK Indonesia 10350
IPO Date
Jul 6, 2021
Website
bmhs.co.id
Business
PT Bundamedik Tbk operates as an Indonesia-based healthcare service provider specializing in hospital management and related medical services. The company offers comprehensive healthcare solutions through its network of facilities, including Bunda Jakarta Woman and Children Hospital, Bunda Jakarta General Hospital, Bunda Margonda General Hospital, Bunda Padang General Hospital, Bunda Ciputat Woman and Children Hospital, Bunda Citra Harapan General Hospital, AZ Zahra Woman and Children Hospital, Bunda Denpasar Woman and Children Hospital; BIC Pacific Place and BIC Vida Bekasi clinics; Morula IVF Indonesia for in vitro fertilization and reproductive sciences via IRSI; Diagnos laboratories for genomics, clinical pathology, radiology, and diagnostic services; Prima Dental Medika for dental care; Bunda Global Pharma for pharmaceutical wholesale and distribution; emergency response services; BMHS Diklat Indonesia for health education and training; and Indonesian Medical Tourism Board (IMTB) initiatives, alongside management consulting for physiotherapy, reproductive technology, oncology, cardiovascular care, and corporate health services. PT Bundamedik Tbk conducts operations across multiple cities in Indonesia, targeting maternal and child health, general medical care, fertility treatments, and specialized diagnostics for individual patients, families, and corporate clients. Founded in 1961 by Dr. Rizal Sini as a maternity clinic and headquartered at Jl. Teuku Cik Ditiro No. 28, Menteng, Jakarta Pusat, the company functions as a subsidiary of PT Bunda Investama Indonesia. In recent developments, PT Bundamedik Tbk acquires a 99.99% stake in PT Medika Sejahtera Bersama (MSB) for IDR 38.99 billion through a share transfer agreement signed on January 31, 2025, with payment in cash to enhance integrated maternal and child hospital services and market share; discloses affiliated transactions including guarantees to subsidiary PT Morula Indonesia in early 2025; faces a IDR 5 billion fine from Indonesia's competition authority in September 2024 for late notification of its 2021 acquisition of 99% in PT Pintu Ilmu; and pursues synergies via partial ownership in PT Morula Indonesia alongside entities like PT Bunda Ipiti Investama and Jinxin Life Asia Healthcare Investment Group.